Former Merck USA President Joins Klotho Neurosciences’ Board of Directors
Klotho Neurosciences (NASDAQ: KLTO) has appointed Riad El-Dada, former US President of Merck, to its Board of Directors. During his tenure at Merck, El-Dada managed over $12 billion in revenue across multiple therapeutic areas and served as Managing Director for Australia and New Zealand operations. His experience includes product development, commercialization, strategic partnerships, and policy engagement through the Healthcare Leadership Council. The appointment aims to strengthen the company's development of S-KL, a patent-protected Klotho gene therapy targeting ALS, Alzheimer's, and Parkinson's diseases.
Klotho Neurosciences (NASDAQ: KLTO) ha nominato Riad El-Dada, ex Presidente della Merck per gli Stati Uniti, nel suo Consiglio di Amministrazione. Durante il suo mandato alla Merck, El-Dada ha gestito oltre 12 miliardi di dollari di fatturato in diversi ambiti terapeutici e ha ricoperto il ruolo di Direttore Generale per le operazioni in Australia e Nuova Zelanda. La sua esperienza include lo sviluppo di prodotti, la commercializzazione, le alleanze strategiche e l'impegno nelle politiche attraverso il Healthcare Leadership Council. Questa nomina mira a rafforzare lo sviluppo dell'S-KL, una terapia genica Klotho protetta da brevetto mirata alle malattie di ALS, Alzheimer e Parkinson.
Klotho Neurosciences (NASDAQ: KLTO) ha nombrado a Riad El-Dada, ex presidente de Merck en EE. UU., para su Junta Directiva. Durante su mandato en Merck, El-Dada gestionó más de 12 mil millones de dólares en ingresos en múltiples áreas terapéuticas y se desempeñó como Director General para las operaciones en Australia y Nueva Zelanda. Su experiencia incluye el desarrollo de productos, la comercialización, asociaciones estratégicas y el compromiso político a través del Healthcare Leadership Council. Esta nombramiento tiene como objetivo fortalecer el desarrollo del S-KL, una terapia génica Klotho protegida por patente dirigida a las enfermedades de ALS, Alzheimer y Parkinson.
Klotho Neurosciences (NASDAQ: KLTO)는 라이야드 엘다다를 이사회에 임명했습니다. 그는 이전에 미국 머크의 회장을 역임했습니다. 머크 재직 중 엘다다는 여러 치료 분야에서 120억 달러 이상의 매출을 관리했으며 호주와 뉴질랜드 운영의 관리 이사로 활동했습니다. 그의 경험에는 제품 개발, 상업화, 전략적 파트너십 및 의료 리더십 회의를 통한 정책 참여가 포함됩니다. 이번 임명은 ALS, 알츠하이머 및 파킨슨병을 목표로 하는 특허 보호 Klotho 유전자 치료제인 S-KL의 개발을 강화하기 위함입니다.
Klotho Neurosciences (NASDAQ: KLTO) a nommé Riad El-Dada, ancien président de Merck aux États-Unis, à son conseil d'administration. Au cours de son mandat chez Merck, El-Dada a géré plus de 12 milliards de dollars de revenus dans plusieurs domaines thérapeutiques et a été Directeur Général pour les opérations en Australie et en Nouvelle-Zélande. Son expérience inclut le développement de produits, la commercialisation, les partenariats stratégiques et l'engagement politique à travers le Healthcare Leadership Council. Cette nomination vise à renforcer le développement du S-KL, une thérapie génique Klotho protégée par un brevet ciblant les maladies de l'ALS, d'Alzheimer et de Parkinson.
Klotho Neurosciences (NASDAQ: KLTO) hat Riad El-Dada, ehemaligen Präsidenten von Merck in den USA, in seinen Vorstand berufen. Während seiner Amtszeit bei Merck verwaltete El-Dada über 12 Milliarden Dollar Umsatz in mehreren therapeutischen Bereichen und war Geschäftsführer der Aktivitäten in Australien und Neuseeland. Seine Erfahrung umfasst Produktentwicklung, Kommerzialisierung, strategische Partnerschaften und politisches Engagement über den Healthcare Leadership Council. Die Ernennung soll die Entwicklung von S-KL stärken, einer patentgeschützten Klotho-Gentherapie, die auf ALS-, Alzheimer- und Parkinson-Erkrankungen abzielt.
- Appointment of former Merck US President with proven track record managing $12B+ revenue
- Addition of executive with extensive pharmaceutical commercialization experience
- Strengthened board expertise in strategic partnerships and product development
- None.
Highly Accomplished Pharmaceutical Leader, Riad El-Dada, Further Enhances Board Expertise
NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for neurodegenerative and age-related disorders, including ALS, Alzheimer’s, and Parkinson’s, today announced the appointment of Riad El-Dada, former US President of Merck, to its Board of Directors.
With decades of leadership in the pharmaceutical industry, Mr. El-Dada brings extensive experience in product development, commercialization, and strategic partnerships. During his tenure as US President of Merck, he oversaw commercial teams across a dozen therapeutic areas, managing over
Mr. El-Dada’s career is marked by impactful achievements, including negotiating key development and commercialization deals, as well as building collaborations across all phases of the pharmaceutical lifecycle. Before joining Merck, he advised Fortune 500 clients as a consultant with McKinsey & Company. He has also served on the Healthcare Leadership Council in Washington, DC, where he actively engaged with policymakers on Capitol Hill.
Dr. Shalom Hirschman, Chair of the Board’s Nominating Committee, commented: “On behalf of the Board, I am thrilled to welcome Riad El-Dada to Klotho Neurosciences. Riad’s unparalleled expertise in pharmaceutical innovation, strategic leadership, and operational excellence will be invaluable as we advance our mission to develop groundbreaking therapies for neurodegenerative diseases. His proven track record of success positions him as a tremendous asset to Klotho Neurosciences as we accelerate the development of our patent-protected Klotho gene therapy, S-KL, aimed at addressing ALS, Alzheimer’s, and Parkinson’s. We are honored to have him join our Board.”
Expressing his enthusiasm, Mr. El-Dada stated: “I am honored to join Klotho Neurosciences’ Board of Directors. The company is developing potentially life-changing therapies using its innovative, patent-protected Klotho anti-aging gene, S-KL. I am eager to contribute to advancing Klotho’s mission, helping realize its vision for transforming the treatment landscape for devastating diseases such as ALS, Alzheimer’s, and Parkinson’s. I look forward to playing my part on the Board where we aim to drive value for our shareholders and, most importantly, bring hope to millions of patients and families worldwide.”
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biopharmaceutical company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the “anti-aging” human Klotho gene (s-KL), and it’s novel delivery system (s-KL/AAV.myo) to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The company’s current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostics. Other assets include clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called Nanoject. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
For more information, contact:
Eric Boyd
Investor Relations
Email: IR@klothoneuro.com
Website: www.klothoneuro.com
Forward-Looking Statements:
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
FAQ
Who did Klotho Neurosciences (KLTO) appoint to its Board of Directors?
What revenue did Riad El-Dada manage at Merck before joining KLTO?
What therapeutic areas is Klotho Neurosciences (KLTO) targeting with its S-KL gene therapy?
